Organization
Hadassah Medical Center
8 abstracts
Abstract
Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.Org: University Hospital Zurich, Aix-Marseille University CHU Timone, Hôpital de la Timone, Department of Cancer Medicine, Gustave Roussy Cancer Centre, Gustave Roussy Cancer Campus,
Abstract
Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Hadassah Medical Center, City of Hope Comprehensive Cancer Center, AbbVie Inc., North Chicago, IL, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
Clinical features of breast cancer in Ashkenazi Jewish carriers of the two founder BRCA1 pathogenic variants.Org: Shaare Zedek Medical Center, Faculty of Medicine, Cairo University, Hebrew University-Hadassah Medical School, Sharett Institute of Oncology, Hadassah Medical Center,
Abstract
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.Org: University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Indiana Blood and & Marrow Transplantation, Franciscan Health, Karmanos Cancer Institute, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway, Sungkyunkwan University School of Medicine, Samsung Medical Center,
Abstract
BELLWAVE-003: A phase 2 dose escalation, confirmation, and cohort expansion study of nemtabrutinib in hematologic malignancies.Org: Hospital Paulistano and Instituto Américas, Tom Baker Cancer Centre, Ankara University School of Medicine, MSC National Research Institute of Oncology, Kraków, Poland, Institut Català d'Oncologia Hospitalet,
Abstract
waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).Org: Hadassah Medical Center, Ankara University School of Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, Institut Català d'Oncologia Hospitalet, Samsung Medical Center,
Abstract
A decision-making tool for first-line treatment in advanced non–small-cell lung cancer based on plasma proteome biomarkers.Org: OncoHost LTD, Heidelberg University Hospital, Heidelberg, Germany, Roswell Park Cancer Institute, Sheba Medical Center, Or-Yeuda, Rambam Health Care,
Abstract
Clinical characteristics, response to poly (adenosine phosphate-ribose) polymerase inhibitors and platinum chemotherapy in patients with lung cancer harboring BRCA mutations.Org: Sharett Institute of Oncology, Hadassah Medical Center, Jerusalem, Israel, Ein Kerem, Factuality of Medicine,